SNPHF (Santen Pharmaceutical Co) Moat Score: 5/10 (As of Jul. 01, 2026)


SNPHF Santen Pharmaceutical Co Ltd SNPHF
81 GF Score
Price $13.05
GF Value $10.29
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Moat Score?

Santen Pharmaceutical Co SNPHF +4.40% 81 Moat Score is 5 as of Jul. 01, 2026. GuruFocus rates SNPHF with a GF Score™ of 81/100 and a GF Value™ of $10.29 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 94.67% on this metric.

Santen Pharmaceutical Co has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Santen Pharmaceutical Co has Narrow Moat: Santen Pharmaceutical has a solid narrow moat due to its valuable intellectual property and patents in ophthalmology. It benefits from strong brand strength and customer loyalty in niche markets. However, it lacks significant network effects and faces competition from larger pharmaceutical companies, limiting its moat to a narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Santen Pharmaceutical Co might have Narrow Moat - Solid narrow moat.

Santen Pharmaceutical Co  (OTCPK:SNPHF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Santen Pharmaceutical Co Moat Score Related Terms

SNPHF vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santen Pharmaceutical Co Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Moat Score falls into.


SNPHF
81GF Score
Santen Pharmaceutical Co Ltd SNPHF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Santen Pharmaceutical Co (SNPHF) has a Moat Score of 5 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Santen Pharmaceutical Co ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Santen Pharmaceutical Co's Moat Score too high?
Santen Pharmaceutical Co's current Moat Score is 5. Based on the distribution chart, Santen Pharmaceutical Co ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Santen Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #55 out of 1031 companies for Moat Score. This places Santen Pharmaceutical Co in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Santen Pharmaceutical Co's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.29, compared to a current price of $13.05 — trading 26.8% above its estimated fair value. The current Moat Score is 5. Santen Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Moat Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 26.8% above its estimated GF Value™ of $10.29. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Moat Score: 5
  • GF Value™: $10.29 vs. price of $13.05 (26.8% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
81GF Score

Get the complete analysis for SNPHF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.29
GF Value